drugset / Trial / NCT00062504
Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas
Phase 2
Terminated
30 enrolled
Teva Branded Pharmaceutical Products R&D, Inc.
National Cancer Institute (NCI) · collab
Parallel-groupTreatment
Summary
To analyze the effect of Talampanel on progression free survival in patients with recurrent high grade gliomas.
Timeline
- Start
- 2003-07
- Primary completion
- 2006-01
- Completion
- 2006-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Talampanel | Small molecule | 10 mg | — |
| Subject | Talampanel | Small molecule | 25 mg | — |
| Subject | Talampanel | Small molecule | 35 mg | — |
| Subject | Talampanel | Small molecule | 50 mg | — |
| Subject | Talampanel | Small molecule | 75 mg | — |